In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $166.09, denoting a +1.44% change from the preceding trading day.

Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's ...

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...

We recently published a list of S&P 500 Dividend Aristocrats List: Sorted By Hedge Fund Sentiment. In this article, we are ...

Nasdaq 100, S&P 500, Dow Jones Industrial Average, Coca-Cola Co. Read MarketBeat.com (Ryan Hasson)'s latest article on Investing.com ...

Escalating concerns over impending tariffs and President Trump's foreign policies have fueled uncertainty and instability in ...

Johnson & Johnson’s stock rose 1.1% on Thursday, reaching $159.56. Trading volume dropped significantly, with 1.7 million ...

As biosimilar versions of a big-selling Johnson & Johnson medicine reach the U.S. market, the health care giant accused one ...

We recently published a list of 10 Best DRIP Stocks To Own Now. In this article, we are going to take a look at where Johnson ...

We recently published a list of 11 Best Performing Dow Stocks So Far in 2025. In this article, we are going to take a look at ...

As of 20 February 2025, the index has steadily increased, rising 14.41% in the last 12 months and 4.21% year to date in 2025.

Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States, the second in a wave of near-copies of the ...